✦ LIBER ✦

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Scribed by Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Mani; Mark J. Ratain

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 66 KB
Volume: 86
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19990801)86:3<528::aid-cncr23>3.0.co;2-r

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of activity. A Phase I study of both agents in combination therapy was conducted.

📜 SIMILAR VOLUMES

A phase I study of ifosfamide with mesna

A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors

✍ Charles B. Pratt; William H. Meyer; Edwin C. Douglass; Laura Bowman; Judith Wili 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

A phase I study of gemcitabine and docet

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

A phase I trial of topotecan and gemcita

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

✍ Weijing Sun; James P. Stevenson; Maryann Gallagher; Bruce Giantonio; Kenneth Alg 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Phase I bioequivalency study of MitoExtr

Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors

✍ Peter Kozuch; Paulo M. Hoff; Kenneth Hess; Jennifer Adams; Robert A. Newman; Fra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

A Phase I–II study of 96-hour infusional

A Phase I–II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent müllerian tumors

✍ Richard T. Penson; Jeffrey G. Supko; Michael V. Seiden; Arlan F. Fuller; Ross S. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

A phase I study of ifosfamide given on a

A phase I study of ifosfamide given on alternate days to treat children with brain tumors

✍ Charles B. Pratt; Edwin C. Douglass; Richard Heideman; Loraine Avery; Stewart J. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 1 views